Table 4 Crude and adjusted hazard ratio of permanent hemodialysis access recreation for different statins.

From: Statins Improve Long Term Patency of Arteriovenous Fistula for Hemodialysis

 

N

event

Person-years

Incidence (%)

HR

Adjused HR

Atorvastatin

 Nonusers

4693

1739

17723.87

9.81

1.0

1.0

 Users

4693

1612

15521.13

10.39

0.99 (0.92–1.06)

0.79 (0.72–0.87)**

Lovastatin

 Nonusers

621

214

2387.40

8.96

1.0

1.0

 Users

621

232

2265.60

10.24

1.13 (0.94–1.36)

0.90 (0.71–1.14)

Simvastatin

 Nonusers

1616

602

6321.88

9.52

1.0

1.0

 Users

1616

566

6050.86

9.35

0.96 (0.86–1.08)

0.72 (0.61–0.84)**

Rosuvastatin

 Nonusers

1115

415

4224.19

9.82

1.0

1.0

 Users

1115

313

2676.11

11.70

0.95 (0.82–1.11)

0.74 (0.59–0.93)*

Fluvastatin

 Nonusers

1106

421

4098.16

10.27

1.0

1.0

 Users

1106

386

3791.23

10.18

0.95 (0.83–1.09)

0.84 (0.70–1.02)

Pravastatin

 Nonusers

582

243

2172.62

11.18

1.0

1.0

 Users

582

221

2181.54

10.13

0.90 (0.75–1.08)

0.72 (0.56–0.92)*

  1. *p < 0.05; **p < 0.001
  2. Covariates adjusted in multivariate models included income, age, sex, area, CHF, CVA, PVD, DM, ASHD, COPD, GI disease, liver disease, dysrhythmia, CABG, PCI, ICD, drugs prescribed before index date (included NSAID, aspirin, acetaminophen, ACEI, ARB, beta-blocker, non-DHP and DHP CCB, acetazolamide, thiazides, loop, potassium sparing diuretics, alpha-blocker, biguanides, sulfonylureas, alpha glucosidase inhibitors, thiazolidinediones, meglitinides, insulin, DPP4 inhibitors, statins, morphine, warfarin, clopidogrel, digoxin).
Back to article page